Addendum
Trastuzumab deruxtecan (breast cancer) – Addendum to Project A25-54
Report documents
-
Addendum
Trastuzumab deruxtecan (breast cancer) – Addendum to Project A25-54
Dossier assessment
Adult patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-116
- Commission
- Commission awarded on 10.09.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-116_en
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed